Cardiology September 25, 2023
Cardiovascular Societies Seek A Board of Their Own September 25, 2023
After months of growing cardiologist backlash against the ABIM’s Maintenance of Certification program, four leading cardiovascular societies collectively announced plans to create a new cardiology board to replace it.
Pharmaceuticals September 21, 2023
Abelacimab Significantly Reduces Bleeding September 21, 2023
Anthos Therapeutics celebrated its Phase II results showing that its Factor XI inhibitor abelacimab significantly reduced bleeding among AFib patients compared to rivaroxaban.
Cardiology September 18, 2023
Cardiology in 2073 September 18, 2023
Most of cardiology today was unknown or in its very early stages fifty years ago, and this forecast suggests that “cardiology will change as much in the next 50 years.”
Pharmaceuticals September 14, 2023
Lorundrostat’s Safe and Effective Blood Pressure Control September 14, 2023
An aldosterone inhibitor called lorundrostat took a step towards becoming the first new antihypertensive agent class in nearly 15 years, after safely and effectively treating patients with uncontrolled blood pressure in a Phase II trial.
Pharmaceuticals September 11, 2023
Zilebesiran Phase 2 Results Show Long-Lasting Blood Pressure Impact September 11, 2023
Zilebesiran’s path towards becoming the first long-lasting antihypertensive medication gained more momentum, with new topline Phase 2 results demonstrating that a single injection significantly reduces systolic blood pressure through six months.
Artificial Intelligence September 7, 2023
The State of Cardiology AI September 7, 2023
The cardiology AI segment is showing more clinical and commercial promise than just about any AI segment in healthcare outside of radiology, and its rapid evolution is worth our attention. Because of that, we’re taking a deep dive into the state of cardiology AI and the key trends driving its growth.
Electrophysiology August 31, 2023
Most Subclinical AF Patients Better Off Without Anticoagulants August 31, 2023
The growing number of people walking around with implantable and wearable cardiac monitoring devices will undoubtedly lead to far more subclinical AFib detections. But the NOAH-AFNET 6 trial provided some much needed reassurance that many of these patients would be better off without anticoagulants.
Surgeries & Interventions August 28, 2023
ReCor Medical Takes Renal Denervation Lead Following FDA Panel Review August 28, 2023
The renal denervation votes are in, and they’re pointing in very different directions for ReCor Medical and Medtronic’s respective RDN devices. The companies argued their premarket approval cases to an FDA expert panel last week, and only ReCor walked away with panel support.
Cardiology Testing August 24, 2023
Simplifying CVD and Renal Assessments with Multimarker Blood Testing August 24, 2023
Blood biomarker tests play a key role in assessing cardiovascular and renal risks in diabetic patients, but a recent AHA study out of Harvard Medical School suggests that a “simple” new multimarker test could significantly improve these assessments and downstream treatment decisions.
Cardiology Guidelines August 21, 2023
HFrEF Treatment’s Guideline Barrier August 21, 2023
Guideline-directed medical therapies (GDMT) for heart failure have proven to be “profoundly effective at reducing morbidity and mortality,” and yet prescription rates for many HFrEF therapies are far too low and inconsistent. To unravel this challenge, a UCLA team analyzed VA data from 178k veterans in 306 Hospital Referral Regions (HRRs) across the US.
Electrophysiology August 17, 2023
Questioning the Cath Lab for Arrhythmia Risk Management August 17, 2023
Many arrhythmia patients take a trip to the cath lab before they end up in the EP lab, but a pair of new studies suggest that many of these “risk management” cath lab procedures are unnecessary - and might even increase risks.
Pharmaceuticals August 14, 2023
Novo Nordisk Expands Weight Loss Pipeline with Inversago Acquisition August 14, 2023
Novo Nordisk added to its leadership position in the white hot weight loss segment, acquiring Canadian biotech Inversago Pharma for up to $1.075 billion depending on certain development and commercial milestones.
Pharmaceuticals August 10, 2023
Wegovy Cuts Weight and Cardiovascular Events August 10, 2023
The hottest medication in the world got even hotter this week after Novo Nordisk revealed that its weight loss drug Wegovy (semaglutide) also reduces major cardiac event risks by 20% - a revelation that could change how GLP-1s are used, perceived, and reimbursed.
Pharmaceuticals August 7, 2023
Novartis and Ionis Double Down on Lp(a) August 7, 2023
Novartis and Ionis Pharmaceuticals doubled down on their Lp(a) alliance, launching a second collaboration focused on developing and commercializing a treatment for patients with lipoprotein(a)-driven cardiovascular disease.
Digital Health August 3, 2023
Hims’ Dual-Action Cardiovascular Health Expansion August 3, 2023
Massive direct-to-consumer health and wellness company, Hims & Hers, announced an unexpected expansion into cardiovascular care last week with the launch of Heart Health by Hims.
Cardiology Pharmaceuticals July 31, 2023
Lilly Shows Tirzepatide Superiority in SURMOUNT-3 and 4 July 31, 2023
Results from Eli Lilly’s SURMOUNT-3 and SURMOUNT-4 trials are in, and they confirmed that its GLP-1 / GIP agonist tirzepatide (aka Mounjaro) drives significant weight loss among obese or overweight adults who don’t have type 2 diabetes.
Cardiology Pharmaceuticals July 27, 2023
Alnylam and Roche’s Long-Lasting Antihypertensive Alliance July 27, 2023
Just days after Alnylam Pharmaceuticals showed that a single injection of zilebesiran can control blood pressure for up to six months, the biotech has joined forces with Roche to usher the mid-stage medication through its clinical trials into clinical use.
Cardiology Pharmaceuticals July 24, 2023
Zilebesiran’s Long-Lasting Antihypertensive Potential July 24, 2023
Could the first long-lasting antihypertensive medication be on the way? Results of a Phase 1 study in NEJM suggests that Alnylam Pharmaceuticals’ zilebesiran is a frontrunner to become that drug, showing that a single injection controls blood pressure for up to six months.
Digital Health July 20, 2023
Astellas Expands into Heart Failure Digital Therapeutics July 20, 2023
Astellas Pharma and Eko Health announced an alliance that will make Eko's digital stethoscope and CVD detection software and Welldoc’s chronic care management capabilities the core components of Astellas’ new Z1608 digital therapeutic for heart failure.
